Printer Friendly

TELIOS COMMENCES ADVANCED PHASE II STUDY FOR OCUNEX OPHTHALMIC SOLUTION

 SAN DIEGO, Aug. 31 /PRNewswire/ -- Telios Pharmaceuticals Inc. (NASDAQ: TLIO) announced today that it has commenced a multicenter Phase II clinical study of the use of OcuNex(TM) ophthalmic solution in the treatment of severe dry eye associated with ocular surface disease. Severe dry eye, also known as keratoconjunctivitis sicca, affects more than 300,000 people in the United States, including patients with Sjogren's syndrome.
 OcuNex ophthalmic solution is comprised of a peptide containing the cell adhesion sequence, RGD (arginine-glycine-aspartic acid) attached to a naturally occurring biopolymer, chondroitin sulfate. The product is designed to promote cell-matrix interactions that result in the restoration of normal corneal structure.
 An early Phase II clinical study conducted in the United States involving 45 patients showed that the benefit of OcuNex ophthalmic solution, as compared to a leading artificial tear, was greatest among those patients with more severe dry eye disease. Also, preliminary analysis of a Phase II study conducted in Japan showed a statistically significant reduction (p<.05) in Rose Bengal staining, a measurement of damaged corneal epithelium, when the product was compared to chondroitin sulfate solution. No significant safety concerns were observed in any of the Phase I and II studies conducted in the United States and Japan.
 The current Phase II clinical trial will be conducted at clinics in Boston, Washington D.C., Durham, N.C., St. Paul, Minn., Denver, San Diego, and Portland, Ore. Severe dry eye patients interested in being screened for the study may call 800-859-9858 for a referral to the nearest clinical site.
 Telios is a leader in the development of a new class of therapeutic products that modify or mimic extracellular matrix functions in tissue repair and disease. The company is applying its proprietary technology to develop products for the treatment of severe and chronic dermal wounds, ophthalmic wounds, fibrotic diseases (such as certain kidney diseases), cardiovascular diseases, and osteoporosis.
 -0- 8/31/93
 /NOTE TO EDITORS: The Phase II clinical trials will be conducted in the following cities: Boston, Washington, D.C., Durham, St. Paul, Denver, San Diego and Portland./
 /CONTACT: Audrey D. Keane, director of Corporate Development Telios Pharmaceuticals Inc., 619-622-2615/
 (TLIO)


CO: Telios Pharmaceuticals Inc. ST: California IN: MTC SU:

LM-MF -- SD001 -- 7318 08/31/93 07:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 31, 1993
Words:375
Previous Article:JUST GETTING STARTED OR GEARING UP FOR GROWTH: AMERITECH WORK-AT-HOME CENTERS CAN HELP
Next Article:COSTCO SALES FOR AUGUST
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters